Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita
March 05 2024 - 7:00AM
Business Wire
Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN),
congratulates Victor Sordillo PE, CSP, MBA, on his recent
appointment as Managing Director of Risk Advisory Services at
Verita CSG, Inc., a provider of holistic insurance and risk
management solutions for commercial line clients.
Mr. Sordillo has been a vital part of Tevogen’s Board of
Directors, contributing to the diversity of thought leadership
within the executive team by way of expertise in leadership, risk
management, and finance as well as his previous roles on boards of
various charitable organizations such as the local chapters of
American Red Cross and United Way.
"Victor's commitment to improving patient access to lifesaving
medicines has greatly contributed to the success of Tevogen Bio,
and I believe his collaboration with Verita will be just as
valuable in bringing innovation to the insurance industry.
Congratulations!” said Ryan Saadi, MD, MPH, Tevogen Bio’s Chief
Executive Officer.
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company
harnessing one of nature’s most powerful immunological weapons,
CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically
unmodified precision T cell therapies for the treatment of
infectious diseases, cancers, and neurological disorders, aiming to
address the significant unmet needs of large patient populations.
Tevogen Leadership believes that sustainability and commercial
success in the current era of healthcare rely on ensuring patient
accessibility through advanced science and innovative business
models. Tevogen has reported positive safety data from its
proof-of-concept clinical trial, and its key intellectual property
assets are wholly owned by the company, not subject to any
third-party licensing agreements. These assets include three
granted patents and twelve pending patents, two of which are
related to artificial intelligence.
Tevogen Bio is driven by a team of highly experienced industry
leaders and distinguished scientists with drug development and
global product launch experience. Tevogen Bio’s leadership believes
that accessible personalized therapeutics are the next frontier of
medicine, and that disruptive business models are required to
sustain medical innovation.
Forward-Looking Statements
This press release contains certain statements that are not
historical facts and are forward-looking statements within the
meaning of the federal securities laws, including statements with
respect to the product candidates, products, markets, and expected
future performance and market opportunities of Tevogen Bio. These
forward-looking statements generally are identified by the words
“believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”
“think,” “strategy,” “future,” “opportunity,” “potential,” “plan,”
“seeks,” “may,” “should,” “will,” “would,” “will be,” “will
continue,” “will likely result,” and similar expressions, but the
absence of these words does not mean that a statement is not
forward-looking. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties.
These forward-looking statements are provided for illustrative
purposes only and are not intended to serve as, and must not be
relied on as, a guarantee, an assurance, a prediction or a
definitive statement of fact or probability. Actual events and
circumstances are difficult or impossible to predict and will
differ from assumptions. Many factors could cause actual future
events to differ materially from the forward-looking statements in
this communication, including but not limited to: (i) the effect of
the recent business combination with Semper Paratus Acquisition
Corporation (the “Business Combination”) on Tevogen’s business
relationships, operating results, and business generally; (ii) the
outcome of any legal proceedings that may be instituted against
Tevogen related to the Business Combination; (iii) changes in the
markets in which Tevogen competes, including with respect to its
competitive landscape, technology evolution, or regulatory changes;
(iv) changes in domestic and global general economic conditions;
(v) the risk that Tevogen may not be able to execute its growth
strategies or may experience difficulties in managing its growth
and expanding operations; (vi) the risk that Tevogen may not be
able to develop and maintain effective internal controls; (vii)
costs related to the Business Combination and the failure to
realize anticipated benefits of the Business Combination; (viii)
the failure to recognize the anticipated benefits of the Business
Combination and to achieve Tevogen’s commercialization and
development plans, and identify and realize additional
opportunities, which may be affected by, among other things,
competition, the ability of Tevogen to grow and manage growth
economically and hire and retain key employees; (ix) the risk that
Tevogen may fail to keep pace with rapid technological developments
to provide new and innovative products and services or make
substantial investments in unsuccessful new products and services;
(x) the ability to develop, license or acquire new therapeutics;
(xi) that Tevogen will need to raise additional capital to execute
its business plan, which may not be available on acceptable terms
or at all; (xii) the risk of product liability or regulatory
lawsuits or proceedings relating to Tevogen’s business; (xiii)
uncertainties inherent in the execution, cost, and completion of
preclinical studies and clinical trials; risks related to
regulatory review, and approval and commercial development; (xiv)
risks associated with intellectual property protection; (xv)
Tevogen’s limited operating history; and (xvi) those factors
discussed in Tevogen’s filings with the SEC and that are contained
in the Proxy Statement/Prospectus relating to the Business
Combination.
The foregoing list of factors is not exhaustive. You should
carefully consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of the Proxy
Statement/Prospectus and other documents to be filed by Tevogen Bio
from time to time with the SEC. These filings identify and address
other important risks and uncertainties that could cause actual
events and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and while Tevogen Bio
may elect to update these forward-looking statements at some point
in the future, they assume no obligation to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by applicable law.
These forward-looking statements should not be relied upon as
representing Tevogen Bio’s assessments as of any date subsequent to
the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240305240921/en/
Tevogen Communications T: 1 877 TEVOGEN, Ext 701
communications@Tevogen.com
Tevogen Bio (NASDAQ:TVGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tevogen Bio (NASDAQ:TVGN)
Historical Stock Chart
From Sep 2023 to Sep 2024